BOZEN, Sud-Tirol, Italy, August 26, 2013 /PRNewswire/ --
Clearly surpassing Intelligent Hospital Systems-RIVA and Baxter-IntelliFill, Health Robotics considerably improved from prior year's 2012 PP&P's National Survey, leapfrogging both IHS-RIVA and IntelliFill, as independently reported by PP&P at:
Gaspar DeViedma, Health Robotics' Executive Vice President stated: "Regardless of this particular independent report from PP&P, or other paid, incomplete, and biased reports such as KLAS, the fact of the matter is that the market has clearly spoken, with Health Robotics' capturing 95% of IV Robot sales in the American market since the company started direct operations in March 2011, and all new major medical center IV Robot sales over the last two years: http://www.health-robotics.com/en/installations/
In its 8th Annual State of Pharmacy Automation 2013 released this month, Pharmacy Purchasing & Products National Survey found that Health Robotics improved to 64% of hospital pharmacists' consideration from its prior year 40% score, achieved in only the first full year after the company started direct operations in the USA, as compared to its competitors' 20 to 25 years head-start in IV Automation. Unlike other industry pay-to-play reports [such as KLAS Research], that lack independence due to their solicitation for both vendor's and hospital's payments, PP&P does not require payment from vendors and/or hospitals, and thus, does not permit paying vendors to edit and/or influence the survey's results,
Mr. DeViedmacontinued: "Pharmacists should compare and contrast from the spin and bias sputtered by Intelligent Hospital Systems' CEO, who unashamedly referred to in a press release as being "# 1 IV Robot in a report that only measured 2 Robots [his own company's and Baxter-IntelliFill] out of eleven companies in the IV Robotics sector". Claiming as Mr. Hansen did to be #1 out of 2, conveniently leaving out the fact that there were 9 companies missing, is hardly a thing to be proud of: http://www.intelligenthospitals.com."
About Health Robotics:
Founded in 2006 and now reaching 80% total IV Robots market share in the world [including over 90% the Oncology Robots global market], Health Robotics is the undisputed leading supplier of life-critical intravenous medication robots, providing almost 500 hospital installations in 5 continents with the only fully-integrated Robotics-based technology, IV Workflow, and manual compounding software automation solutions. Health Robotics' second generation products [i.v.STATION, i.v.SOFT, and i.v.STATION ONCO] have been found [through scientific and peer-reviewed studies,,] to greatly contribute to ease hospitals' growing pressures to improve patient safety, increase throughput, and contain costs,. Through the effective and efficient production of sterile, accurate, tamper-evident and ready-to-administer IVs, Health Robotics' medical devices and integrated workflow solutions help hospitals eliminate life-threatening drug and diluent exchange errors, improve drug potency, decrease other medical mistakes and sterility risks, work more efficiently,, reduce waste and controlled substances' diversion, reduce pharmacy technician upper-limb injuries, and diminish the gap between rising patient volume/acuity and scarce nursing and pharmacy staff. For more information, please visit: http://www.health-robotics.com
1. Intelligent Hospital Systems/Technology 2000 started in IV Automation in 1989: Am J Hosp Pharm 46(11): 2286--93 1989. St. Boniface Hospital, Winnipeg.
2. 11 Competitors in IV Automation: Baxter, Fresenius, Health Robotics, Integra, Intelligent Hospital Systems, Kiro, Loccioni, Panasonic, Pharmoduct, Yasukawa, and Yuyama.
3. Impact of Robotic Antineoplastic Preparation on Safety, Workflow, Costs. Seger, Churchill, Keohane, Belisle, Wong, Sylvester, Chesnick, Burdick, Wien, Cotugno, Bates, and Rothschild. Brigham & Women's Hospital, Massachusetts College of Pharmacy, and Harvard Medical School. Journal of Oncology Practice, Nov. 2012, Volume 8, number 6.
4. Validation of an automated method for compounding monoclonal antibody patient doses: case studies of Avastin®, Remicade®, and Herceptin®. Peters, Capelle, Arvinte, van de Garde. St. Antonius Hospital. mAbs January 2013, Volume 5, Issue 1.
5. Comparing the upper limb disorder risks associated with manual and automated cytotoxic compounding. McLeod, Zochowska, Leonard, Crow, Jacklin, Dean, Franklin. Imperial College Healthcare NHS Trust. European Journal of Hospital Pharmacy April 2012.
For additional information, please contact:
SOURCE Health Robotics